AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15352911 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 45
Study 11235793 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 h of sleep deprivation
Number of subjects: 39
Study 11235793 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol up to 0.1% BAC
Number of subjects: 39
Study 11235793 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian rhythm effect
Number of subjects: 39
Study 11235793 — intervention group
Group type: COMPARATOR
Intervention: Drivers (compared to controls)
Number of subjects: 39
Study 10404791 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (HRT)
Number of subjects: 595
Study 10404791 — intervention group
Group type: COMPARATOR
Intervention: No hormonal replacement therapy (Control)
Number of subjects: 595
Study 7550205 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural drainage and manual chest percussion (Treatment A)
Number of subjects: 14
Study 7550205 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing through a commercial device with oscillating positive expiratory pressure (Treatment B)
Number of subjects: 14
Study 2404590 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum cytodiagnosis evaluated by trained cytotechnologists
Number of subjects: 130
Study 2404590 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer A
Number of subjects: 130
Study 2404590 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer B
Number of subjects: 130
Study 2404590 — intervention group
Group type: EXPERIMENTAL
Intervention: Within observer discordant readings
Number of subjects: 130
Study 6987028 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (single oral doses of 25, 50, 75, 100, or 150 mg)
Number of subjects: 5
Study 6987028 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (multiple doses at 25, 50, or 100 mg thrice daily)
Number of subjects: 5
Study 6987028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30709668 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 0
Study 30709668 — intervention group
Group type: COMPARATOR
Intervention: Surgical Aortic Valve Replacement (SAVR)
Number of subjects: 0
Study 27761980 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri CP2305 administered daily for 4 weeks
Number of subjects: 0
Study 27761980 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri CP2305
Number of subjects: 0
Study 25833666 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist medication review with face-to-face pharmacist prescribing
Number of subjects: 125
Study 25833666 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist medication review with feedback to general practitioner
Number of subjects: 125
Study 25833666 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 125
Study 24219193 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise intervention (1-hour session, three times a week for 16 weeks)
Number of subjects: 30
Study 24219193 — intervention group
Group type: COMPARATOR
Intervention: Control group (no activity during the same period)
Number of subjects: 30
Study 21054515 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO), dosage and duration not specified
Number of subjects: 135
Study 21054515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 19824054 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC (salmeterol 50 microg/FP 100 microg twice daily)
Number of subjects: 283
Study 19824054 — intervention group
Group type: COMPARATOR
Intervention: FP (fluticasone proprionate 200 microg twice daily)
Number of subjects: 283
Study 19824054 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC
Number of subjects: 283
Study 19824054 — intervention group
Group type: COMPARATOR
Intervention: FP
Number of subjects: 283
Study 18528511 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine case management (N = 844)
Number of subjects: 1665
Study 18528511 — intervention group
Group type: COMPARATOR
Intervention: Usual care (N = 821)
Number of subjects: 1665
Study 12919181 — intervention group
Group type: EXPERIMENTAL
Intervention: YM337 + ASA + UFH
Number of subjects: 18
Study 12919181 — intervention group
Group type: EXPERIMENTAL
Intervention: YM337 alone
Number of subjects: 18
Study 12919181 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA + UFH + YM337
Number of subjects: 18
Study 12919181 — intervention group
Group type: COMPARATOR
Intervention: ASA (placebo) + UFH (placebo) + YM337
Number of subjects: 18
Study 12919181 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA + UFH
Number of subjects: 18
Study 10952772 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine (Gem Vin) at dose level I (1000/25 mg/m(2))
Number of subjects: 126
Study 10952772 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine (Gem Vin) at dose level II (1200/25 mg/m(2))
Number of subjects: 126
Study 10952772 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine (Gem Vin) at dose level III (1000/30 mg/m(2))
Number of subjects: 126
Study 10952772 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine (Gem Vin) overall
Number of subjects: 126
Study 10952772 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine (Gem Vin)
Number of subjects: 126
Study 9002810 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMA‐glutaraldehyde bonding agent
Number of subjects: 40
Study 9002810 — intervention group
Group type: COMPARATOR
Intervention: formamide‐containing bonding agent
Number of subjects: 40
Study 1361274 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure recordings
Number of subjects: 0
Study 1361274 — intervention group
Group type: COMPARATOR
Intervention: Office blood pressure measurements
Number of subjects: 0
Study 6238209 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate (MPA) therapy
Number of subjects: 27
Study 3539830 — intervention group
Group type: EXPERIMENTAL
Intervention: Biostim (8 mg daily)
Number of subjects: 20
Study 3539830 — intervention group
Group type: EXPERIMENTAL
Intervention: Biostim (2 mg daily)
Number of subjects: 20
Study 3539830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31811333 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (single bolus)
Number of subjects: 0
Study 31811333 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 31811333 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (for low cortisol level patients)
Number of subjects: 0
Study 31811333 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (for high cortisol level patients)
Number of subjects: 0
Study 29709490 — intervention group
Group type: EXPERIMENTAL
Intervention: Monomorbid schizophrenia
Number of subjects: 0
Study 29709490 — intervention group
Group type: EXPERIMENTAL
Intervention: Both psychiatric and substance use comorbidities
Number of subjects: 0
Study 29709490 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid substance use alone
Number of subjects: 0
Study 26554619 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hyoscine‐N‐butylbromide
Number of subjects: 150
Study 24874316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortexin (10 mg three times a day intramuscularly, two courses)
Number of subjects: 272
Study 24874316 — intervention group
Group type: COMPARATOR
Intervention: Cortexin (10 mg three times a day intramuscularly, one course)
Number of subjects: 272
Study 24874316 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two courses)
Number of subjects: 272
Study 22509337 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (500 mg twice daily)
Number of subjects: 148
Study 22509337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 22509337 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 148
Study 20116145 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) pathway
Number of subjects: 452
Study 20116145 — intervention group
Group type: COMPARATOR
Intervention: Conventional perioperative care
Number of subjects: 452
Study 18937844 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar graph (BG group)
Number of subjects: 150
Study 18937844 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar graph plus frequency format diagram (BG+FF group)
Number of subjects: 150
Study 15720087 — intervention group
Group type: EXPERIMENTAL
Intervention: 585 nm pulsed-dye laser (single treatment)
Number of subjects: 58
Study 15720087 — intervention group
Group type: EXPERIMENTAL
Intervention: 585 nm pulsed-dye laser (double treatment)
Number of subjects: 58
Study 15720087 — intervention group
Group type: COMPARATOR
Intervention: Control (periorbital region without treatment)
Number of subjects: 58
Study 12882865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO) therapy, applied twice a day, 5 days a week for 2 weeks, each session lasting 90 min at 2.5 ATA.
Number of subjects: 28
Study 12882865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO) therapy
Number of subjects: 28
Study 12882865 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 28
Study 10959507 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment protocol (LTP) with 60 microg PGE1, 5 days each week for 4 weeks, followed by twice a week for 4 weeks, then no drugs for 3 months.
Number of subjects: 980
Study 10959507 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment protocol (STP) with 20 microg on the first day, 40 microg in the afternoon, and 60 microg on the second day, then 60 microg bid for subsequent cycles.
Number of subjects: 980
Study 10959507 — intervention group
Group type: COMPARATOR
Intervention: Cost analysis of LTP
Number of subjects: 980
Study 10959507 — intervention group
Group type: COMPARATOR
Intervention: Cost analysis of STP
Number of subjects: 980
Study 8648221 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microgram of rHA0
Number of subjects: 100
Study 8648221 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 microgram of rHA0
Number of subjects: 100
Study 8648221 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 microgram of rHA0
Number of subjects: 100
Study 8648221 — intervention group
Group type: COMPARATOR
Intervention: Subvirion trivalent influenza vaccine
Number of subjects: 100
Study 8648221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1465038 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms oestradiol administered as vaginal pessaries daily for 3 weeks prior to surgery
Number of subjects: 48
Study 1465038 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered as vaginal pessaries daily for 3 weeks prior to surgery
Number of subjects: 48
Study 6371367 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorhydrocortisone
Number of subjects: 40
Study 6371367 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 40
Study 6371367 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 40
Study 6371367 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 40
Study 31376560 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-grade heterotopic ossification (HO)
Number of subjects: 0
Study 31376560 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade heterotopic ossification (HO)
Number of subjects: 0
Study 31376560 — intervention group
Group type: COMPARATOR
Intervention: No heterotopic ossification (HO)
Number of subjects: 0
Study 31376560 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 0
Study 30411133 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound diamond instrument
Number of subjects: 32
Study 30411133 — intervention group
Group type: COMPARATOR
Intervention: High-speed hand piece with regular diamond burs
Number of subjects: 32
Study 27595110 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel containing 3% ethanolic extract of Brazilian green propolis (EEP-B)
Number of subjects: 0
Study 27595110 — intervention group
Group type: COMPARATOR
Intervention: Gel without EEP-B
Number of subjects: 0
Study 27595110 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel containing EEP-B
Number of subjects: 0
Study 24744316 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g/d RM + 25 g of maltodextrin/d
Number of subjects: 14
Study 24744316 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g/d RM + 0 g/d maltodextrin
Number of subjects: 14
Study 24744316 — intervention group
Group type: COMPARATOR
Intervention: 0 g/d RM + 50 g/d maltodextrin (placebo)
Number of subjects: 14
Study 24744316 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g/d RM
Number of subjects: 14
Study 24744316 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g/d RM
Number of subjects: 14
Study 22738882 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-gauge needle
Number of subjects: 250
Study 22738882 — intervention group
Group type: COMPARATOR
Intervention: 18-gauge needle
Number of subjects: 250
Study 22738882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 250
Study 20167145 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD/FM pMDI 160/9 micrograms twice daily (320/18 micrograms daily)
Number of subjects: 752
Study 20167145 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD/FM pMDI 320/9 micrograms once daily (evening)
Number of subjects: 752
Study 20167145 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD/FM pMDI 160/9 micrograms once daily (evening)
Number of subjects: 752
Study 20167145 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD pMDI 320 micrograms once daily (evening)
Number of subjects: 752
Study 20167145 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 752
Study 18431588 — intervention group
Group type: EXPERIMENTAL
Intervention: TA-assisted PPV
Number of subjects: 774
Study 18431588 — intervention group
Group type: COMPARATOR
Intervention: Conventional PPV
Number of subjects: 774
Study 16412352 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K(1) group (10 mg per day for 2 to 7 days, antenatal administration)
Number of subjects: 177
Study 16412352 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin K(1) treatment)
Number of subjects: 177
Study 16412352 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K(1) group
Number of subjects: 177
Study 16412352 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 177
Study 12852709 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1% ophthalmic solution
Number of subjects: 131
Study 12852709 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops (artificial tears)
Number of subjects: 131
Study 10803723 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Imputation (MI)
Number of subjects: 0
Study 10803723 — intervention group
Group type: COMPARATOR
Intervention: Methods for handling informative dropouts
Number of subjects: 0
Study 8645026 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-emetic administration group
Number of subjects: 98
Study 8645026 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration group
Number of subjects: 98
Study 8645026 — intervention group
Group type: EXPERIMENTAL
Intervention: Total score of 13 descriptive items
Number of subjects: 98
Study 8645026 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear analogue scale
Number of subjects: 98
Study 8645026 — intervention group
Group type: EXPERIMENTAL
Intervention: Face scale
Number of subjects: 98
Study 8645026 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological scale
Number of subjects: 98
Study 8645026 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological scale
Number of subjects: 98
Study 8645026 — intervention group
Group type: EXPERIMENTAL
Intervention: Active scale
Number of subjects: 98
Study 8645026 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive items
Number of subjects: 98
Study 8645026 — intervention group
Group type: EXPERIMENTAL
Intervention: QOL measurement
Number of subjects: 98
Study 1463154 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. midazolam (17 patients; 2.85 +/- 0.84 mg)
Number of subjects: 50
Study 1463154 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual flunitrazepam (16 patients; 0.005 mg/kg)
Number of subjects: 50
Study 1463154 — intervention group
Group type: COMPARATOR
Intervention: no sedation (17 patients; controls)
Number of subjects: 50
Study 2418736 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfacetamide-polymyxin B-neomycin-gramicidin (TSP)
Number of subjects: 0
Study 2418736 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-polymyxin B (TP)
Number of subjects: 0
Study 30739305 — intervention group
Group type: EXPERIMENTAL
Intervention: PFT-guided DAPT de-escalation (switch from prasugrel to clopidogrel)
Number of subjects: 151
Study 30739305 — intervention group
Group type: COMPARATOR
Intervention: Uniform prasugrel (control group)
Number of subjects: 151
Study 30739305 — intervention group
Group type: COMPARATOR
Intervention: Control group (prasugrel)
Number of subjects: 151
Study 30739305 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalation group (clopidogrel)
Number of subjects: 151
Study 29632098 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventicus BP smartphone algorithm
Number of subjects: 32
Study 29632098 — intervention group
Group type: COMPARATOR
Intervention: Reference device (Omron‐HBP‐1300)
Number of subjects: 32
Study 27070747 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 % maximal contraction
Number of subjects: 20
Study 27070747 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 % maximal contraction
Number of subjects: 20
Study 24953293 — intervention group
Group type: EXPERIMENTAL
Intervention: Rush oral immunotherapy (OIT) with peanuts, ingested 3-5 times a day every 30 minutes, increasing the dose by 20% each time, goal dose 3.5-7 g
Number of subjects: 18
Study 22706327 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg twice daily
Number of subjects: 116
Study 22706327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 20148372 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg/kg
Number of subjects: 10
Study 20148372 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg/kg
Number of subjects: 10
Study 20148372 — intervention group
Group type: COMPARATOR
Intervention: Albuterol plus caffeine placebo
Number of subjects: 10
Study 20148372 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol with 3 mg/kg caffeine
Number of subjects: 10
Study 20148372 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol with 6 mg/kg caffeine
Number of subjects: 10
Study 20148372 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol with 9 mg/kg caffeine
Number of subjects: 10
Study 18356845 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 94
Study 18356845 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Training (AT)
Number of subjects: 94
Study 18356845 — intervention group
Group type: COMPARATOR
Intervention: No Training (NT)
Number of subjects: 94
Study 15988611 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene FRC
Number of subjects: 14
Study 15988611 — intervention group
Group type: COMPARATOR
Intervention: Ceramic
Number of subjects: 14
Study 15988611 — intervention group
Group type: COMPARATOR
Intervention: Restorative composite
Number of subjects: 14
Study 15988611 — intervention group
Group type: COMPARATOR
Intervention: Glass FRC
Number of subjects: 14
Study 12090979 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic fresh platelets
Number of subjects: 20
Study 12090979 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cryopreserved platelets
Number of subjects: 20
Study 10525070 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorprothixene administered intravenously
Number of subjects: 8
Study 10525070 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorprothixene administered orally
Number of subjects: 8
Study 7551370 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-24180 (20 mg twice a day)
Number of subjects: 13
Study 7551370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2281761 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional cast allowing free range of motion
Number of subjects: 100
Study 2281761 — intervention group
Group type: COMPARATOR
Intervention: Dorsal/ulnar plaster cast immobilizing the wrist and joints
Number of subjects: 100
Study 2281761 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional cast
Number of subjects: 100
Study 233160 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose fluphenazine decanoate (1.25 mg to 5.0 mg biweekly)
Number of subjects: 57
Study 233160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 30189768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutures
Number of subjects: 746
Study 30189768 — intervention group
Group type: COMPARATOR
Intervention: Staples
Number of subjects: 746
Study 31474134 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 235
Study 31474134 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (TXA)
Number of subjects: 235
Study 29100681 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine group (n = 11)
Number of subjects: 23
Study 29100681 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 12)
Number of subjects: 23
Study 26338891 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 55
Study 26338891 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 55
Study 26338891 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fructose Corn Syrup (HFCS55)
Number of subjects: 55
Study 26338891 — intervention group
Group type: EXPERIMENTAL
Intervention: All sugars (honey, sucrose, HFCS55)
Number of subjects: 55
Study 26338891 — intervention group
Group type: COMPARATOR
Intervention: Control (no sugar intake)
Number of subjects: 55
Study 23147161 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcidin-25 levels (measured with mass spectrometry)
Number of subjects: 405